Home | Welcome to Contract Pharma   
Last Updated Saturday, December 20 2014

Print

Financial Report: Alexion



Published February 14, 2013
Alexion

4Q Revenues: $320.5 million (+41%)

4Q Earnings: $81.0 million (+68%)

FY Revenues: $1.1 billion (+45%)

FY Earnings: $254.8 million (+45%)

Comments: Soliris sales were $320.5 million in the quarter, up 41%, and $1.1 billion for the year, up 45% driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS).


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On